Biomea Fusion, Inc.
Close on Oct 19, 2026
- Market cap
- $60.46M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2026 Ended Mar 31, 2026 | May 11, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 24, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | After market close | – | $-0.27 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 5, 2025 | After market close | – | $-0.80 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 31, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 29, 2024 | After market close | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 31, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 1, 2024 | After market close | – | $-0.98 | – |
| Q3 FY2023 Ended Sep 30, 2023 | Oct 30, 2023 | After market close | – | $-0.80 | – |
| Q2 FY2023 Ended Jun 30, 2023 | Jul 31, 2023 | After market close | – | $-0.70 | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 2, 2023 | After market close | – | $-0.98 | – |
Press releases
Announcements Biomea Fusion filed with the SEC
Overweight or Obese Adult Participants Week 4 Topline Results October 13, 2026
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Biomea Fusion Announces Phase 1 Results for BMF-650, its
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
FUSION CONFERENCE CALL 28 APRIL 2026 Icovamenib in Type 1 Diabetes Exhibit 99.1
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
2026 J.P. Morgan Healthcare Conference
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
unknown risks, uncertainties, and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Biomea Fusion Announces Proposed Public Offering of Securities
Material agreement · Other events · EX-99.1 to Form 8-K
Biomea Fusion Announces Pricing of Public Offering of Securities
Material agreement · Other events · EX-99.2 to Form 8-K
Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Biomea Fusion Announces Proposed Public Offering of Securities
Material agreement · Other events · EX-99.1 to Form 8-K
Biomea Fusion Announces Pricing of Public Offering of Securities
Material agreement · Other events · EX-99.2 to Form 8-K
Legal Disclaimer & Forward-Looking Statement Certain statements in
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Biomea Fusion Announces Leadership Transition
Listing notice · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Biomea Fusion to Become a Diabetes &
Other events · EX-99.1 to Form 8-K
Corporate Presentation 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 15, 2025
Other events · EX-99.2 to Form 8-K
Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
COVALENT-111 Topline Results - Conference Call December 17, 2024 Agenda
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Preclinical Data Combining icovamenib with a GLP-1-Based Therapy & Biomea’s Oral GLP-1 RA Candidate BMF-650 October 30, 2024 Exhibit 99.1
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
Other events · EX-99.1 to Form 8-K
Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold
Other events · EX-99.1 to Form 8-K
Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
Other events · EX-99.1 to Form 8-K
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up
Other events · EX-99.1 to Form 8-K
DURABLE GLYCEMIC CONTROL WITH BMF-219 DURING OFF-TREATMENT PERIOD AT
Other events · EX-99.2 to Form 8-K
KEY OBSERVATIONS FROM THE DOSE-ESCALATION PORTION OF COVALENT-111, A
Other events · EX-99.3 to Form 8-K
Biomea Fusion Reports Third Quarter 2023 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Biomea Fusion Reports Second Quarter 2023 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
BMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient Population
Other events · EX-99.1 to Form 8-K
Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent FLT3 Inhibitor
Other events · EX-99.1 to Form 8-K
Biomea Fusion Reports First Quarter 2023 Financial Results and Corporate Highlights
Results of operations · EX-99 to Form 8-K